Comparison of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a retrospective study with 3-year survival analysis
Journal of Cancer Research and Clinical Oncology · 25.10.2024 · 150 (10)
DOI: 10.1007/s00432-024-06004-w ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 25.10.2024. Verfasst von Peiyuan Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophagectomy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China, the Science and Technology Program of Fujian Province, Startup Fund for scientific research,Fujian Medical University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Neoadjuvant chemoimmunotherapy (nCIT) for locally advanced esophageal squamous cell cancer (ESCC) has shown short-term benefits, but long-term survival outcomes are unclear. This study compares nCIT and neoadjuvant chemotherapy (nCT) in resectable ESCC. PATIENTS AND METHODS: A retrospective analysis was conducted on ESCC patients who underwent nCT or nCIT followed by esophagectomy. Propensity score matching (PSM) with a caliper of 0.02 was employed to minimize bias. The primary endpoints included disease-free survival (DFS) and overall survival (OS). RESULTS: A total of 131 comparable pairs of ESCC patients receiving nCT and nCIT were selected for the final analysis. The nCIT had higher rates of pathological complete response (pCR) and major pathological response (mPR) compared to nCT. Additionally, nCIT led to significant tumor down-staging, higher rates of R0 resection, and increased lymph node clearance during surgery. Patients who received nCIT exhibited improved disease-free survival (DFS) and overall survival (OS) at the 3-year follow-up. The incidence of distant and mixed relapses was lower in the nCIT group compared to the nCT group. However, the risk of locoregional relapse was comparable between the two groups. Subgroup analyses showed that the benefits of nCIT were generally observed across most patient subgroups. Interestingly, in patients without pCR or mPR, nCIT still demonstrated better survival benefits than nCT. CONCLUSION: nCIT demonstrated superior pathological response rates and improved 3-year DFS and OS compared to nCT alone in locally advanced ESCC, but long-term survival validation is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Oncology Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
- Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, China.
- Fujian Provincial Key Laboratory of Tumor Biotherapy, Fuzhou, China.
- Department of Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
- Department of Thoracic Oncology Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China. shuoyanliu2010@163.com.
Förderung
- the National Natural Science Foundation of China
- the Science and Technology Program of Fujian Province
- Startup Fund for scientific research,Fujian Medical University
Zitieren
APA
Wang, P., Chen, Y., Lei, M., He, H., Zhang, D., Lin, J., Lin, H., Wei, W., Chen, P., Zhuang, F., Chen, W., Zhou, H., Gao, P., Liu, S., & Wang, F. (2024). Comparison of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a retrospective study with 3-year survival analysis. Journal of Cancer Research and Clinical Oncology, 150(10). https://doi.org/10.1007/s00432-024-06004-w
Vancouver
Wang P, Chen Y, Lei M, He H, Zhang D, Lin J, et al. Comparison of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a retrospective study with 3-year survival analysis. Journal of Cancer Research and Clinical Oncology. 2024;150(10). doi:10.1007/s00432-024-06004-w
BibTeX
@article{Wang2024,
author = {Wang, Peiyuan and Chen, Yujie and Lei, Mengxia and He, Hao and Zhang, Derong and Lin, Junpeng and Lin, Hui and Wei, Wenwei and Chen, Peng and Zhuang, Fengnian and Chen, Weijie and Zhou, Hang and Gao, Pengqiang and Liu, Shuoyan and Wang, Feng},
title = {Comparison of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a retrospective study with 3-year survival analysis},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
volume = {150},
number = {10},
doi = {10.1007/s00432-024-06004-w}
}
EUVIMED